ಶ್ವಾಸಕೋಶದ ಕ್ಯಾನ್ಸರ್ (ನಾನ್-ಸ್ಮಾಲ್ ಸೆಲ್)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
ಎಲ್ಲಿಗೆ ಹೋಗಬೇಕು
ಈ ಟ್ರಯಲ್ಗಾಗಿ ಭಾರತದ 12 ಆಸ್ಪತ್ರೆಗಳು ರೋಗಿಗಳನ್ನು ತೆಗೆದುಕೊಳ್ಳುತ್ತಿವೆ.
ರಿಜಿಸ್ಟ್ರಿ ಸಾರಾಂಶ (ತಾಂತ್ರಿಕ)
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Sponsor: Eli Lilly and Company
ClinicalTrials.gov ನಲ್ಲಿ NCT06890598
Last updated on the registry 7 Oct 2026 · read by us 20 Oct 2026